Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
AKTIENPREIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionDaiwa Securities Group Inc.
Latest Disclosed Ownership25,364 shares
Latest Disclosed Value $ 8,392,187
Daiwa Securities Group Inc. ownership in DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Daiwa Securities Group Inc. filed a 13F-HR form disclosing ownership of 25,364 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $7,246,495 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 25,999 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -2.44% during the quarter. The current value of the position is $6,607,322 USD.

Daiwa Securities Group Inc. has a history of taking positions in derivatives of the underlying security (DUL) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:DUL / Alnylam Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,364 -635 -2.44 8,392 83,820.00 0.0142
2026-02-10 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,999 10,503 67.78 10 42.86 0.0330
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,496 2,555 19.74 7 75.00 0.0238
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,941 35 0.27 4 33.33 0.0156
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,906 355 2.83 3 50.00 0.0147
2025-02-07 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,551 479 3.97 3 -33.33 0.0132
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,072 780 6.91 3 50.00 0.0153
2024-08-07 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,292 371 3.40 3 100.00 0.0146
2024-05-02 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,921 116 1.07 2 -50.00 0.0092
2024-01-31 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,805 400 3.84 2 100.00 0.0129
2023-11-01 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,405 -114 -1.08 2 0.00 0.0131
2023-07-31 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,519 71 0.68 2 -50.00 0.0132
2023-05-02 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 10,448 610 6.20 2 0.00 0.0146
2023-02-06 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,838 9,738 9,738.00 2 -97.85 0.0180
2022-11-02 2022-09-30 13F ALNYLAM PHARMACEUTICALS PUT 02043Q957 100 100 93 0.0008
2022-11-02 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,268 2,255
2022-08-09 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,265 312 3.48 1,351 -7.59 0.0103
2022-04-29 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,953 534 6.34 1,462 2.38 0.0068
2022-02-03 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,419 -76 -0.89 1,428 -10.97 0.0084
2021-11-05 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,495 2,697 46.52 1,604 63.17 0.0105
2021-08-06 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,798 -2,015 -25.79 983 -10.88 0.0066
2021-05-03 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,813 2,399 44.31 1,103 56.68 0.0082
2021-02-04 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,414 -436 -7.45 704 -17.37 0.0054
2020-11-02 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,850 475 8.84 852 45.64 0.0077
2020-08-11 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,375 0 0.00 585 0.00 0.0123
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,375 0 0.00 585 -5.49 0.0061
2020-01-31 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,375 -79 -1.45 619 41.00 0.0051
2019-11-04 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,454 1,648 43.30 439 59.06 0.0037
2019-07-24 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,806 0 0.00 276 -22.47 0.0024
2019-04-26 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,806 28 0.74 356 29.45 0.0031
2019-02-05 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,778 350 10.21 275 -8.33 0.0026
2018-11-01 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,428 0 0.00 300 -11.24 0.0025
2018-07-30 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,428 0 0.00 338 -17.16 0.0027
2018-05-02 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,428 728 26.96 408 18.95 0.0033
2018-02-06 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,700 2,700 343 0.0024
2017-02-01 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -1,800 -100.00 0 -100.00
2017-01-10 2016-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,800 0 0.00 122 22.00 0.0007
2016-11-04 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,800 122
2016-07-25 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,800 0 0.00 100 -11.50 0.0006
2016-05-12 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,800 200 12.50 113 -25.17 0.0007
2016-02-04 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,600 0 0.00 151 17.05 0.0010
2015-11-10 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,600 400 33.33 129 -10.42 0.0009
2015-08-05 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,200 1,200 144 0.0010
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-11-02 2022-09-30 13F ALNYLAM PHARMACEUTICALS PUT 100 93 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.